Sun Pharma gets exclusive global rights to commercialise 'Fibromun', an anti-cancer immunotherapy product

Oct 01, 2024

Under this agreement, Sun Pharma will hold exclusive global rights to commercialise Fibromun, while Philogen will continue conducting pivotal clinical trials, pursue marketing authorisation...